Latest Conference Coverage


Unlocking the Novel Risk Factors of Alzheimer Disease With Genetic Diversity in Research

Unlocking the Novel Risk Factors of Alzheimer Disease With Genetic Diversity in Research

August 17th 2023

Adam Naj, PhD, genetic epidemiologist at the University of Pennsylvania, discussed the importance of collecting genetic data from diverse ancestries to investigate the risk of Alzheimer Disease.


Empowering Behavior Change in Migraine Through Motivational Interviewing: Elizabeth Seng, PhD

Empowering Behavior Change in Migraine Through Motivational Interviewing: Elizabeth Seng, PhD

August 16th 2023

The associate professor at Yeshiva University and Albert Einstein College of Medicine discussed the significance of motivational interviewing as a means for providers to engage with their patients and the harmful impact of societal stereotypes on individuals with migraine. [WATCH TIME: 5 minutes]


Seeking Clarity in Patient Stratification of Parkinson Disease: Mazen Elkurd, DO

Seeking Clarity in Patient Stratification of Parkinson Disease: Mazen Elkurd, DO

August 14th 2023

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]


Proper Ways to Engage Underserved Populations in Pain Medicine: Burel Goodin, PhD

Proper Ways to Engage Underserved Populations in Pain Medicine: Burel Goodin, PhD

August 10th 2023

The professor of anesthesiology at Washington University in St. Louis provided perspective on the respect and approach that comes with conducting research in underserved or impoverished communities. [WATCH TIME: 4 minutes]


Enhancing Care and Diagnostic Criteria for Essential Tremor and Dementia with Lewy Bodies: David Shprecher, DO, MSci, FAAN

Enhancing Care and Diagnostic Criteria for Essential Tremor and Dementia with Lewy Bodies: David Shprecher, DO, MSci, FAAN

August 10th 2023

The director of movement disorders at the Banner Sun Health Research Institute talked about alternative approaches for treating essential tremor beyond medications, and developments in the diagnostic criteria for Lewy body disorders. [WATCH TIME: 5 minutes]


Navigating the Cognitive Screening Toolbox: Dustin Hammers, PhD

Navigating the Cognitive Screening Toolbox: Dustin Hammers, PhD

August 8th 2023

The associate professor of neurology at the Indiana University School of Medicine discussed the screening paradigm for Alzheimer disease, and the reluctancy to use new digital tools over traditional methods. [WATCH TIME: 6 minutes]


Botulinumtoxins in the Management of Movement Disorders: Laxman Bahroo, DO

Botulinumtoxins in the Management of Movement Disorders: Laxman Bahroo, DO

August 8th 2023

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]


Addressing Patient Hesitancy in Parkinson Treatment With Education: Mazen Elkurd, DO

Addressing Patient Hesitancy in Parkinson Treatment With Education: Mazen Elkurd, DO

August 7th 2023

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]


Recapping Research From 2023 Alzheimer's Association International Conference

Recapping Research From 2023 Alzheimer's Association International Conference

August 6th 2023

As a recap from AAIC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.


Alzheimer's Association International Conference 2023: Top Expert Interviews

Alzheimer's Association International Conference 2023: Top Expert Interviews

August 5th 2023

A group of experts in the care of patients with neurological conditions—Kumar B. Rajan, PhD; Christina Jensen-Dahm, MD, PhD; Nicole Fowler, PhD; Nicholas Ashton, PhD; Jazmyn Muhammad, BS—shared their perspectives on hot topics of treatment and management in Alzheimer disease from the 2023 Alzheimer's Association International Conference.


Incorporation of Biomarkers, Synaptic Plasticity, in Treatment Paradigm for Alzheimer Disease: Alessio Travaglia, PhD

Incorporation of Biomarkers, Synaptic Plasticity, in Treatment Paradigm for Alzheimer Disease: Alessio Travaglia, PhD

August 4th 2023

The director at the Foundation for the National Institutes of Health discussed relevant biomarkers for Alzheimer disease and their role as novel therapeutics continue to emerge. [WATCH TIME: 5 minutes]


Challenges in Diagnosis and Treatment for Atypical Parkinsonian Disorders: David Shprecher, DO, MSci, FAAN

Challenges in Diagnosis and Treatment for Atypical Parkinsonian Disorders: David Shprecher, DO, MSci, FAAN

August 4th 2023

The director of movement disorders at the Banner Sun Health Research Institute discussed the challenges in diagnosing atypical Parkinsonian disorders and the potential role of biomarkers in improving diagnostic accuracy. [WATCH TIME: 5 minutes]


Innovative Epigenome Editing Adds to Precision Medicine Approach for Alzheimer Disease

Innovative Epigenome Editing Adds to Precision Medicine Approach for Alzheimer Disease

August 3rd 2023

Boris Kantor, PhD, associate research professor of neurobiology, and Ornit Chiba-Falek, PhD, professor in neurology, both faculty at Duke University, discussed research on an innovative epigenome therapy targeting the APOE gene, a significant genetic risk factor for Alzheimer disease.


The Promise of Gene Therapies for the Management of Parkinson Disease: Mazen Elkurd, DO

The Promise of Gene Therapies for the Management of Parkinson Disease: Mazen Elkurd, DO

August 3rd 2023

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]


Incorporating Digital Cognitive Assessments in Real-World Practice: Nicole Fowler, PhD

Incorporating Digital Cognitive Assessments in Real-World Practice: Nicole Fowler, PhD

August 2nd 2023

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]


Uncovering Ethnic, Racial Differences in Multiple Sclerosis Onset: Farren B. S. Briggs, PhD, ScM

Uncovering Ethnic, Racial Differences in Multiple Sclerosis Onset: Farren B. S. Briggs, PhD, ScM

August 2nd 2023

The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about the presentation of multiple sclerosis in Latinx individuals compared with White Americans. [WATCH TIME: 5 minutes]


Enhancing Consistency in Neuroimaging With AI and Image Harmonization: Lianrui Zuo, MSE

Enhancing Consistency in Neuroimaging With AI and Image Harmonization: Lianrui Zuo, MSE

August 1st 2023

The PhD student in the department of electrical and computer engineering at Johns Hopkins University discussed the use of artificial intelligence and image harmonization techniques to address the challenges caused by multisite effects in neuroimaging. [WATCH TIME: 4 minutes]


Ensuring Safe Pregnancy and Postpartum Care for Patients With Multiple Sclerosis: Anna Shah, MD

Ensuring Safe Pregnancy and Postpartum Care for Patients With Multiple Sclerosis: Anna Shah, MD

August 1st 2023

The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]


Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DO

Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DO

July 31st 2023

The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]


Comparing Ublituximab and Teriflunomide in Improving Fatigue in MS: Enrique Alvarez, MD, PhD

Comparing Ublituximab and Teriflunomide in Improving Fatigue in MS: Enrique Alvarez, MD, PhD

July 31st 2023

The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]


Epigenetic Therapy Demonstrates Efficacy in APOE Reduction for Alzheimer Disease

Epigenetic Therapy Demonstrates Efficacy in APOE Reduction for Alzheimer Disease

July 30th 2023

Research shows that carrying the APOE e4 variant significantly increases lifetime risk for late-onset Alzheimer disease, and additional evidence suggests that lowering the variant expression may be a promising therapeutic target for the disease.


Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhD

Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhD

July 28th 2023

The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]


Targeting Neuroinflammation as a Novel Approach in Brain Health for Alzheimer Disease: RJ Tesi, MD

Targeting Neuroinflammation as a Novel Approach in Brain Health for Alzheimer Disease: RJ Tesi, MD

July 27th 2023

The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]


Integrating Blood-Based Biomarkers as a Revised Approach to Diagnosing Alzheimer Disease

Integrating Blood-Based Biomarkers as a Revised Approach to Diagnosing Alzheimer Disease

July 27th 2023

Maria Carrillo, PhD, chief science officer for the Alzheimer's Association, talked about the release of the updated diagnostic guidelines for Alzheimer disease, which incorporate plasma-based biomarkers.


High Prevalence of CAA-Related Lesions in APOE ε4/4 Homozygotes With Early Alzheimer disease

High Prevalence of CAA-Related Lesions in APOE ε4/4 Homozygotes With Early Alzheimer disease

July 26th 2023

Results suggest that the high burden of cerebral amyloid angiopathy-related lesions most likely underlies the 30%-60% incidence of amyloid-related imaging abnormalities in APOE e4/4 carriers treated with approved amyloid therapies.


Multiple Frameworks Better Interpret Alzheimer Trial Results to Meaningful Benefits

Multiple Frameworks Better Interpret Alzheimer Trial Results to Meaningful Benefits

July 26th 2023

Based on a collection of data from clinical trials in Alzheimer disease, the best way to represent and translate the findings to meaningful benefits is through the use of multiple frameworks.


The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD

The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD

July 26th 2023

The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]


NeuroVoices: Alessio Travaglia, PhD, on Utilizing Available Alzheimer Biomarkers Properly

NeuroVoices: Alessio Travaglia, PhD, on Utilizing Available Alzheimer Biomarkers Properly

July 26th 2023

The director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.


Efficacy of Antiamyloid Therapies Shown Over Long-Term Alzheimer Trajectory

Efficacy of Antiamyloid Therapies Shown Over Long-Term Alzheimer Trajectory

July 25th 2023

A slowing of disease progression by 30% would result in clearly meaningful differences in patients with mild cognitive impairment and mild dementia.


Assessing the Impact of Gut Microbiota on Neuroprotection in Alzheimer Disease: Yannick J. Wadop Ngouongo, PhD

Assessing the Impact of Gut Microbiota on Neuroprotection in Alzheimer Disease: Yannick J. Wadop Ngouongo, PhD

July 25th 2023

The postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]

© 2024 MJH Life Sciences

All rights reserved.